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Phenotypic and genetic analysis of
cognitive performance in Major Depressive
Disorder in the Generation Scotland:
Scottish Family Health Study
Joeri J. Meijsen1,2, Archie Campbell 1, Caroline Hayward 3, David J. Porteous 1,2, Ian J. Deary2,4,
Riccardo E. Marioni1,2 and Kristin K. Nicodemus 1,2
Abstract
Lower performances in cognitive ability in individuals with Major Depressive Disorder (MDD) have been observed on
multiple occasions. Understanding cognitive performance in MDD could provide a wider insight in the aetiology of
MDD as a whole. Using a large, well characterised cohort (N= 7012), we tested for: differences in cognitive
performance by MDD status and a gene (single SNP or polygenic score) by MDD interaction effect on cognitive
performance. Linear regression was used to assess the association between cognitive performance and MDD status in
a case-control, single-episode–recurrent MDD and control-recurrent MDD study design. Test scores on verbal
declarative memory, executive functioning, vocabulary, and processing speed were examined. Cognitive performance
measures showing a significant difference between groups were subsequently analysed for genetic associations.
Those with recurrent MDD have lower processing speed versus controls and single-episode MDD (β=−2.44,
p= 3.6 × 10−04; β= -2.86, p= 1.8 × 10−03, respectively). There were significantly higher vocabulary scores in MDD
cases versus controls (β= 0.79, p= 2.0 × 10−06), and for recurrent MDD versus controls (β= 0.95, p= 5.8 × 10−05).
Observed differences could not be linked to significant single-locus associations. Polygenic scores created from a
processing speed meta-analysis GWAS explained 1% of variation in processing speed performance in the single-
episode versus recurrent MDD study (p= 1.7 × 10−03) and 0.5% of variation in the control versus recurrent MDD study
(p= 1.6 × 10−10). Individuals with recurrent MDD showed lower processing speed and executive function while
showing higher vocabulary performance. Within MDD, persons with recurrent episodes show lower processing speed
and executive function scores relative to individuals experiencing a single episode.
Introduction
Major Depressive Disorder (MDD) is common mental
disorder affecting at least 1 in 10 in the United Kingdom1
and is a leading cause of disability worldwide. Showing a
SNP-based heritability of ~30%2,3 and a twin-based
estimate of ~40%4, MDD has a substantial genetic com-
ponent. It has been shown that individuals suffering from
MDD show lower performance in cognitive domains such
as executive function (EF), memory, language and atten-
tion5–7. The identification and quantification of lower
cognitive performance in MDD could lead to a better
understanding of the underlying aetiology of depression,
to improve treatment of patients, or as an endophenotype
for subsequent studies investigating the genetic archi-
tecture of MDD. These targeted approaches could possi-
bly lay the groundwork to improve the mental health of
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MDD patients and therefore lower the burden MDD has
on society.
Despite the high prevalence of MDD, cognitive lower
scores in MDD have not been as widely studied as in other
psychiatric disorders such as bipolar disorder8 and schi-
zophrenia8,9. Snyder et al.5 performed an extensive and
the largest-to-date meta-analysis of cognitive perfor-
mance in MDD, focussing mainly on tasks that measure
executive function (EF) with the exception of two non-EF
tests measuring vocabulary (language) and digit symbol
substitution (processing speed, but is also considered by
some to be a component of EF). They observed that MDD
patients showed a lower performance in phonemic verbal
fluency and digit symbol measures. That is, MDD patients
produced significantly fewer words than healthy control
individuals and recoded significantly fewer symbols to
digits in digit symbol measures. Vocabulary performance
was observed to be lower in MDD patients; however, the
effect was not significant. Logical memory (LM)
immediate and delayed (both measuring verbal declarative
memory) have been less well studied compared to other
cognitive measures in depression. Lim et al.6 conducted
the largest meta-analysis study of LM to date (N logical
memory immediate= 291; N logical memory delayed=
348). They observed that MDD patients performed sig-
nificantly less well than controls on both LM immediate
and delayed. This result has been previously reported by
smaller studies not included in the Lim et al. study10,11,
with one exception12. Significant lower performances
were also observed in the attention domain6, via the digit
span test and continuous performance test where MDD
patients performed slower compared to controls. The
final domain examined, visuospatial processing (immedi-
ate and delayed visual memory), showed no differences
between MDD patients and controls6.
As the genomic underpinnings of MDD are poorly
understood13, we examined genomic associations with
cognitive differences as observed in our study as an
endophenotype strategy. Using the extensively pheno-
typed Generation Scotland Cohort Study, we sought to:
(a) investigate whether cognitive ability in MDD patients
differs from controls without MDD or reported mental
illness, (b) assess whether cognitive performance differs
between single-episode MDD versus recurrent MDD, (c)
investigate cognitive performance between controls and
recurrent MDD and (d) to reduce multiple testing we
performed genome-wide single locus, genome-wide sin-
gle-locus interaction, polygenic and polygenic interaction
analyses only on cognitive performance tests showing a
significant difference within study designs. This study
represents the largest single cohort study investigating the
association of cognitive performance in depression using a
formal clinical diagnosis of MDD and incorporating
genomic association analyses. The largest single cohort
study investigating cognitive performance in depression is
the UK Biobank cohort study7 however that study relies
on self-reported MDD status and does not examine
genetic factors.
Materials and methods
Cohort data and phenotyping
Generation Scotland: the Scottish Family Health
Study (GS:SFHS) is a family-based cohort study sampled
from the general population in Scotland (www.
generationscotland.org)14,15. The study design has been
widely documented14,15. In short, between 2006 and 2011
over 24,000 subjects were recruited into the study. The
initial sample of study subjects (N= 7953) were registered
with general medical practitioners, between 35 and 65
years, and from five regions of Scotland. These initial
study subjects were asked to bring a relative within the
age range 18–99 to the baseline data collection. Partici-
pants were asked to fill in health, lifestyle and family
history questionnaires and answer a 30min interview
which included questions about possible mental ill health.
If participants answered positively on either of the 2
mental health screening questions (“Have you ever seen
anybody for emotional or psychiatric problems?” and
“Was there ever a time when you, or someone else,
thought you should see someone because of the way you
were feeling or acting?”) (N= 4539), they were asked to
take part in a Structured Clinical Interview for DSM-IV
(SCID)16, focussing on mood disorders. Individuals
answering “no” to both questions were assigned to the
control group. Individuals who completed the SCID but
did not meet the criteria for MDD or bipolar disorder
were subsequently assigned to the control group17 (N=
1727). Finally, individuals who were invited for the SCID
interview but refused to take part (N= 507) were not
assigned to either case or control group3.
Four cognitive domains were measured in Generation
Scotland: processing speed (Wechsler Digit Symbol Sub-
stitution Test; recoding symbols to digits18—DST), verbal
declarative memory (Wechsler Logical Memory Test; sum
of immediate and delayed recall of an oral story19—LM1
and LM2), executive functioning (the phonemic verbal
fluency test; using the letters C, F, and L, each for one
minute20—VFT), language (the Mill Hill Vocabulary
Scale, Junior and Senior Synonyms combined—finding a
synonym of a given word21—MHVS) and the difference
between logical memory immediate and delayed
(LM1–LM2). The correlation between scores on tests of
these different cognitive domains are reported in Sup-
plementary Tables S1-S4.
In addition to age and sex, we selected lifestyle factors
(self-reported smoking and alcohol intake), socio-
economic status (the Scottish Index of Multiple Depri-
vation22), medication usage (anti-depressants and mood
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stabilisers) and 15 genetic principal components to con-
trol for population stratification. These variables have
been previously used as covariates in Cullen et al. 20157 to
investigate cognitive differences in depression using the
UK Biobank cohort.
Genetic data
DNA of 20,128 GS:SFHS participants was analysed by
means of high density genome-wide bead array genotyp-
ing (Illumina OmniExpress 700K SNP GWAS and 250K
exome chip). We selected a set of unrelated individuals for
use in our analyses, to remove the influence of shared
environments. We removed single nucleotide poly-
morphisms (SNPs) and individuals with a missingness of
>1% and removed rare SNPs with a minor allele frequency
<0.01 leaving 557,292 SNPs for analysis. We used
Genome-wide Complex Trait Analysis23 to extract a list of
genetically unrelated individuals from a predefined list of
participants with a known MDD SCID diagnosis or con-
trols. Seven thousand, one hundred and seventy-two
unrelated individuals (relatedness<0.025, corresponding
to second degree cousins) were selected, of which 1042
individuals (14.5%) were diagnosed with either single or
recurrent depression. One hundred and five individuals
were removed due to the lack of self-reported medical
background information. Another 25 individuals with
self-reported Alzheimer’s and/or Parkinson’s disease were
removed leading to a total of 7012 individuals, of which
1021 individuals (14.5%) were diagnosed with a form of
depression.
Statistical analysis
Phenotypic differences
We used phi coefficients and Spearman correlation
coefficients to determine the level of correlation between
the pool of potential covariates and MDD case-control,
single-recurrent or control-recurrent status. As a con-
tinuous variable, age was assessed using the Spearman
correlation coefficient. As all other variables were binary,
their correlations were assessed using the phi coefficient,
with associated p-values from either a χ2 or Fisher’s exact
test. The Fisher’s exact test was used when observed cell
counts in the 2 × 2 contingency table were <5. No
potential covariate was strongly correlated with MDD
case-control (Supplementary Table S5), single-recurrent
(Supplementary Table S6) or control-recurrent (Supple-
mentary Table S7) status aside from age, sex and medi-
cation usage in the case-control study and solely
medication usage in both the single-recurrent and
control-recurrent MDD study, as expected. To keep in
line with Cullen et al., 2015 all covariates (sex, age, alcohol
consumption, smoking tobacco, medication usage,
socioeconomic status and 15 principal components) were
included in the full model.
Multiple regression analysis was performed for each
cognitive test and the diagnosis label before and after
controlling for covariates. We used the following models:
a baseline model (1):
Cognitive ability testk ¼ β0 þ βdiagnosis labeldiagnosis label
ð1Þ
and a full model (2):
Cognitive ability testk ¼ β0 þ βdiagnosis labeldiagnosis label
þP
n
i¼1
βi Covariatesi
ð2Þ
We observed that medication usage contained many
missing values (52%), with only a small percentage of all
participants answering positively (5.1%). Therefore, we
performed model 2 and all subsequent analyses twice (1)
including medication usage (M2A) and (2) excluding
medication usage (M2B) as a covariate. A Bonferroni
significance level of p < 8.3 × 10−03 (p= 0.05/6 cognitive
tests) was used. All models were run using the R Statis-
tical Computing Environment24 v 3.1.0.
Single-Locus analysis
We performed a Genome-Wide Association Study
(GWAS) for the cognitive performance variables that
showed a significant difference in the phenotypic analyses.
We further tested whether each SNP’s association with
cognitive performance depended on MDD status via a
Genome-Wide by Environment Interaction Study
(GWEIS). The GWAS analyses can be seen as a baseline
model and GWEIS as a measure of non-additive effects
for SNP and depression case status. The standard Bon-
ferroni significance level of p < 5 × 10−08 is conservative,
as many SNPs are in linkage disequilibrium thus statistical
tests are not independent. Therefore, we applied a less
conservative significant level p < 1.52 × 10−07 derived
from the Genetic type 1 Error Calculator (GEC)25. All
models were run using PLINK version v1.90b1g.
Polygenic analysis
Polygenic Risk Scores (PGRS) were calculated for five p-
value threshold ranges (0–0.01, 0–0.05, 0–0.1, 0–0.5, 0–1)
using summary output from the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE)
meta-analysis GWAS of DST and similar tests that con-
trolled for sex, age, assessment centre, education and
community26. Generation Scotland is a part of the
CHARGE consortium but was not included in this spe-
cific meta-GWAS study. The CHARGE consortium per-
formed a sample size weighted meta-analysis because of
the differences in the test methodology and measurement
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units. The z-statistic was weighted by the effective sample
size (sample size × (observed dosage variance/expected
dosage variance)) for each SNP. We pruned the Genera-
tion Scotland dataset for linkage disequilibrium (window
size= 50 kb, step size= 5 kb and r2 threshold= 0.25) and
converted the CHARGE z-statistics to standardised beta
coefficients using the z-score and standard error provided
by CHARGE. We performed a linear regression model
between the DST and the polygenic risk scores as well as a
model including polygenic risk score-by-MDD status
interaction in a controls-recurrent MDD and single-
recurrent MDD study. Consistently with previous ana-
lyses, we restricted our polygenic score analysis to the
groups where we had observed significant differences. We
controlled for all covariates and the number of valid
genotypes in a model that did not include medication
usage. Figure 1 shows a graphic representation of per-
formed analyses.
Results
Descriptive statistics
We observed significant differences in the distributions
of sex, age, alcohol consumption, smoking tobacco,
medication usage and socioeconomic status across MDD
status with a higher frequency of females (69–72%),
tobacco smokers (23–26.8%) and medication users in the
MDD case group (Table 1). Within MDD cases, alcohol
drinkers represented a significant lower frequency in the
recurrent MDD (83.5%) group than the single-episode
MDD (88.8%) but a higher frequency in medication
usage. On average, controls were slightly but significantly
older than cases with MDD and lived in less deprived
areas.
Cognitive association by depression status
We performed three linear regression analyses for each
cognitive test (the dependent variable). The predictor
variable was MDD diagnosis, classified as either control-
MDD, single-episode–recurrent MDD or control-
recurrent MDD. No other covariates were considered in
these baseline models (Table 2). No significant association
was observed between MDD and cognitive test scores,
except for digit symbol substitution in the single-
episode–recurrent comparison (β=−3.41, p= 5.8 ×
10–04), with the recurrent MDD group recode
fewer symbols to digit compared to single-episode MDD
group.
We then performed linear regression on the full model,
including all covariates that were used in Cullen et al.7,
which includes medication usage (Supplementary Table
S8). We observed a significant difference after correcting
for multiple testing in the MHVS in both the control-
MDD and control-recurrent MDD study. Individuals with
depression had higher scores in the MHVS, identifying on
average 0.66 more synonyms relative to controls (β= 0.66,
p= 2.96 × 10−03). Between controls and individuals with
recurrent MDD, participants with recurrent depression
performed even higher, with 1.07 more synonyms iden-
tified (p= 6.0 × 10−04).
When leaving out medication usage (Table 3) we
observed the same significant higher performance of the
MHVS in the MDD and recurrent MDD group in the
control-MDD (β= 0.79, p= 2.02 × 10−06) and control-
recurrent MDD (β= 0.95, p= 5.8 × 10−05) study design.
Individuals with recurrent MDD recoded significantly
fewer symbols back to digits compared to their
study design counterparts in the single-episode–recurrent
Fig. 1 M1= no covariates, M2A= controlling for all covariates and M2B= controlling for all covariates except medication
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(β=−2.86, p= 1.8 × 10−03) and control-recurrent MDD
(β=−2.44, p= 3.6 × 10−04) study designs
Polygenic score analysis
In the single-episode–recurrent study design, the DST
PGRS was significantly associated with DST performance
at all but two p-value thresholds (Bonferroni p= 0.01;
0.05/5 PGRS ranges), indicating that the DST polygenic
risk score explained a significant amount of variation
(most significant polygenic score: R2 1%, p-value thresh-
old= 0.1, p= 1.66 × 10−03) in performance among MDD
cases (Table 4). We observed significant statistical asso-
ciation with each PGRS range in the control-recurrent
MDD study design with the PGRS explaining between
0.13 and 0.5% of variation (Table 4). However, the effect
of the DST polygenic score did not differ between single-
episode–recurrent cases nor between controls and
recurrent MDD cases. We did not observe a PGRS by
MDD group interaction on DST performance (Supple-
mentary Table S9).
Single-locus analysis
GWAS (Supplementary Figure S1a-b) and GWEIS
(Supplementary Figure S2a-b) analyses was performed on
MHVS in the control-MDD and control-recurrent MDD
study designs excluding medication usage. No SNP was
observed below the GEC significance threshold in the
MHVS analyses (GEC p= 1.52 × 10−07). The same ana-
lysis was performed for DST in the single-
episode–recurrent and control-recurrent MDD study
designs without controlling for medication usage (Sup-
plementary Figures S3a-b and S4a-b). We did not observe
a significant association between genomic variation and
DST. Both the strongest non-significant GWAS and
GWEIS hit were associated with digit symbol perfor-
mance and observed in the single-episode–recurrent
MDD study design. SNP rs10829637 (p= 3.3 × 10−07)
located on chromosome 10 in LOC107984280 was the
most significant GWAS hit and rs911684 (p= 6.7 ×
10−07) located on chromosome 14 in LOC100506999 was
the most significant GWEIS hit. Other GWAS and
Table 1 Demographics and medical history by MDD case status
MDD Status
Control Single Recurrent
Covariate N= 5991 N= 488 N= 533
Sex (N, % Female, 0 NA) 3252 (54) 336 (69) 384 (72)*
Age (M, SD, 0 NA) 51.7 (13.8) 49.1 (12.6) 50.1 (11.1)*
Alcohol (N, % Drinking, 107 NA) 5410 (91.6) 424 (88.8) 437 (83.5)
Smoking (N, % Smoking, 90 NA) 837 (14.2) 111 (23) 141 (26.8)*
Medication (N, % Using, 3595 NA) 73 (2.49) 31 (12.4) 71 (29.8)
SES (M, SD, 363 NA) 4080 (1819.3) 3836 (1853.1) 3422.7 (1966.4)
*All association show significant group differences at 0.05, corrected for multiple testing except for single-episode versus recurrent MDD
Table 2 Association between diagnosis label and cognitive performance in both study designs, without controlling for
covariates
Control-MDD Single-Recurrent MDD Control-Recurrent MDD
β Pr(>|t|) N β Pr(>|t|) N β Pr(>|t|) N
LM1 0.20 0.12 6974 −0.56 0.01 1021 −0.06 0.72 6486
LM2 0.21 0.13 6936 −0.52 0.03 1016 −0.03 0.86 6452
LM1–LM2 −0.03 0.59 6936 −0.02 0.86 1016 −0.04 0.61 6452
DTS −0.02 0.96 6936 −3.41 5.8E−04 1011 −1.65 0.02 6452
VFT 0.03 0.93 6934 −0.03 0.96 1019 0.01 0.97 6447
MHVS 0.05 0.75 6887 0.26 0.37 1013 0.17 0.41 6401
Bolded results are significant after Bonferroni correction
DST digit symbol substitution test, LM1 Logical memory immediate, LM2 logical memory delayed, MHVS Mill Hill vocabulary score, VFT verbal fluency total
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GWEIS results can be found in Supplementary Figure
S5a-b, S6a-b.
Discussion
This study of cognitive performance in MDD is the
largest single cohort study with a formal clinical diagnosis
of MDD and incorporating genomic association analyses.
The only larger single cohort study is UK Biobank, which
does not contain a formal clinical diagnosis of MDD and
did not investigate genetics association. Moreover, the
cognitive battery used in Generation Scotland is stan-
dardised and validated on large representative samples
using pre-existing evidence while the cognitive battery
used in UK Biobank was bespoke and designed for UK
Biobank itself.
We observed significantly higher MHVS scores in MDD
cases versus controls, and between recurrent depression
versus controls with and without controlling for medica-
tion usage, with’cases’ performing higher than the latter in
both studies. The same directionality of effect was
observed in UKB by Cullen et al.7; they also observed a
significant higher score in vocabulary performance in
MDD case groups compared to controls. We also
observed significant lower performance of DST between
recurrent and single-episode MDD cases, and between
recurrent MDD and controls; however, in this case the
‘cases’ performed less well in both study designs. We also
observed a significant amount of variation explained in
DST performance using the CHARGE consortium DST
polygenic risk score; however, this result was observed
across cases and controls and did not differ by case status,
indicating that the DST polygenic risk score may not be a
useful endophenotype for depression.
Our results are consistent with the largest meta-analysis
of case-control differences in digit symbol coding per-
formance, which found that individuals with depression
performed significantly lower than controls4. One pre-
vious study not included in the recent meta-analysis4
examining differences in digit symbol coding performance
between individuals with depression (current (N= 37) or
previous (N= 81)) and controls (N= 50) found no sig-
nificant difference between the three groups, but the
sample size was modest27. We also report no significant
differences between cases and controls or single-episode
Table 3 Association between diagnosis label and cognitive performance in both study designs, after controlling for all
covariates except medication
Control-MDD Single-Recurrent MDD Control-Recurrent MDD
β Pr(>|t|) N β Pr(>|t|) N β Pr(>|t|) N
LM1 0.19 0.18 6447 −0.41 0.09 923 −5.0E−03 0.97 6008
LM2 0.15 0.31 6410 −0.36 0.16 918 −0.02 0.88 5975
LM1–LM2 0.01 0.89 6410 −0.03 0.80 918 6.3E−03 0.95 5975
DST −1.09 0.03 6411 −2.86 1.8E−03 913 −2.44 3.6E−04 5976
VFT 0.89 0.04 6417 0.30 0.69 921 1.04 0.06 5979
MHVS 0.79 2.02E−06 6372 0.42 0.13 916 0.95 5.8E−05 5935
Bolded results are significant after Bonferroni correction
DST digit symbol substitution test, LM1 Logical memory immediate, LM2 logical memory delayed, MHVS Mill Hill vocabulary score, VFT verbal fluency total
Table 4 Association between DST performance and PGRS derived from the DST meta-analysis of the CHARGE
consortium
Single-Recurrent MDD Control-Recurrent MDD
Range Direction Pr(>|t|) R2 (%) Direction Pr(>|t|) R2 (%)
0–0.01 + 0.14 0.48 + 1.63E−03 0.13
0–0.05 + 4.75E−03 0.85 + 9.95E−06 0.23
0–0.1 + 1.66E−03 1 + 5.12E−08 0.36
0–0.5 + 0.011 0.66 + 7.83E−10 0.46
0–1 + 8.42E−03 0.7 + 1.61E−10 0.5
Bolded results are significant after Bonferroni correction
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versus recurrent MDD on vocabulary, also consistent with
Snyder et al4. However, we were unable to replicate some
results previously reported in the literature5–7,10–12,28,29.
Snyder et al.4 observed significant lower performance in
phonemic verbal fluency between cases and controls
whereas we observed no significant difference. One pos-
sible reason is through the inclusion of people in the
control group that have symptoms of depression but do
not meet the criteria of being diagnosed with MDD, in
other words, misclassification of controls, which may have
biased our estimates toward the null. Misclassification of
controls as MDD participants might be possible due to
the screening questions: “Have you ever seen anybody for
emotional or psychiatric problems?” and “Was there ever a
time when you, or someone else, thought you should see
someone because of the way you were feeling or acting?”.
However, this is unlikely due to the subsequent SCID
interview given by a trained clinical nurse. Given that this
interview was given to all MDD cases in GS:SFHS, mis-
classification would be less likely between single-episode
MDD versus recurrent MDD. Second, publication bias
could have influenced results from meta-analyses. Our
sample size, although the second largest to investigate
MDD and cognition to date, may be underpowered to
detect small differences in cognitive performance.
Although we removed individuals with Alzheimer and
Parkinson’s disease and controlled for smoking and
alcohol intake, we did not control for other disorders that
may affect cognition. Many previous studies focused on
clinical populations, whereas our study is population
based; clinical populations may have more severe forms of
depression. The use of simpler models in meta-analyses,
which do not control for covariates, may obscure signals.
Finally, observed cognitive performance in MDD in the
literature are mainly observed in large meta-analyses
which increases the study heterogeneity, while our results
are derived from a much more homogeneous single
cohort study. However, both Snyder et al.4 and Lim et al.5
observed significant heterogeneity and subsequently
applied random-effects meta-analytic models that do not
assume homogeneity of effect between studies. We also
were not able to assess all cognitive domains which could
show signs of cognitive impairments in MDD, such as
visuospatial processing and attention6. Finally, we were
unable to control for the effects of antidepressant use on
cognitive performance in the full sample, which may lead
to poorer performance in cases9.
Cognitive differences between single-episode and
recurrent MDD have been not as well studied as differ-
ences between MDD cases and controls30,31. Talarowska
et al.30 compared the cognitive performance of 210
patients with MDD (single-episode N= 60, recurrent
N= 150) and observed that the cognitive domains of
executive functioning, memory and processing speed
showed significant lower performance in recurrent MDD
in relation to single-episode MDD. The largest study to
date to assess cognitive differences between single-
episode and recurrent depression has been the UK Bio-
bank study7. Cullen et al. (2015) observed higher perfor-
mance in single-episode MDD vs controls (numeric and
prospective memory), however moderate and severe
MDD groups performed lower (e.g. reaction time and
numeric memory) compared to both the single MDD and
control group.
Cullen et al. 2015 observed the same counter-intuitive
higher performance in vocabulary for MDD cases com-
pared to controls and provided several possible explana-
tions for this. It may include differential selection
(depressed individuals are more likely to participate than
controls), differential recall (cognitive test is associated
with greater recall), higher health literacy (individuals
with a higher intelligence are quicker to spot possible
health issues and therefore quicker to see a GP) or resi-
dual confounding.7 As vocabulary is a crystallised intelli-
gence measure where the tests demand recall ability, and
as we observed the same higher performance in a second
large population-based cohort, we hypothesise that dif-
ferential recall and higher health literacy are the most
plausible explanations.
That we did not observe a significant genome-wide hit
for MDD was unsurprising as it is a clinically hetero-
geneous disorder with multiple SNPs of small effect,
which would be difficult to observe without very large
sample sizes. We controlled for LD structure in GWAS/
GWEIS by applying a less conservative GEC significance
threshold which takes into account LD between SNPs. We
compared p-values of SNPs associated with depression in
a large cohort study32 with our results from the GWEIS
studies (Supplementary Table S10). Four SNPs over-
lapped with those available in Generation Scotland and
for 18 SNPs we used 52 proxy SNPs (r2 > 0.8). We
observed a consistent positive association with p-value
<0.05 for the GWEIS of MHVS (both case-control and
control-recurrent) and for the GWEIS of DST in control-
recurrent analyses for SNP rs4143229 which is intronic
and located in ENOX1. A recent GWAS of antidepressant
treatment response at 12 weeks to selective serotonin
reuptake inhibitors (SSRIs) showed suggestive association
with another intronic SNP in ENOX1, rs1753844433.
Using Quanto34 for gene-by-environment power calcula-
tions, setting α= 0.05, two-sided, and using a MAF of 0.5
(as our top SNP had a MAF of 0.48), and observed MDD
proportion and distribution of DSST, we concluded that a
sample size of 2885 individuals was required to detect an
interaction effect at 80% power. Although a significant
amount of variation in DST was explained by the
CHARGE consortium DST polygenic score, it was not
specific to MDD cases and the effect did not vary by MDD
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case status. Polygenic scores often explain only a small
amount of variation in endophenotypes. In this study, we
looked for main and polygenic effects; it might be possible
that more variation can be explained by incorporating
possible genetic interactions between loci and/or the
environment or interactions of two or more loci.
The main strength of this study is that is has assessed
the association between MDD and cognitive ability in a
large homogeneous population sample, using standar-
dised tests and outcome measures across all participants.
This represents a significant advantage over previous
studies that used either meta-analytic (combination of
effects across studies) or mega-analytic (combining
individual-level data across studies) methods to improve
statistical power. The division of the dataset in three study
designs based on MDD diagnosis allowed us to assess
cognitive performance based on MDD severity. Limita-
tions of this study are the sample size (N= 7012) which
results in a low powered interaction analysis, under-
reporting of antidepressant and mood stabiliser medica-
tion usage (<40%) and finally certain cognitive domains
are not measured in the Generation Scotland cognitive
battery, i.e., visuospatial perception.
In conclusion, we have shown that cognitive perfor-
mance in some domains significantly differs between
controls and MDD groups but also within MDD groups.
This difference could not be linked to single-locus asso-
ciations but a small proportion of variation could be
explained by means of a polygenic approach.
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